Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC; Duravelo-2).

Yohann Loriot, Arlene O. Siefker-Radtke, Terence W. Friedlander et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps4619

TPS4619 Background: Zelenectide pevedotin (zele; BT8009) is a Bicycle Toxin Conjugate (BTC), comprising a highly selective bicyclic peptide targeting Nect...

Long-term survival and treatment efficacy in dMMR/MSI-H rectal cancer: A real-world cohort from seven large medical college–affiliated hospitals.

Siyuan Mi, Xingyu Feng, Jianhui Chen et al. Jun 01, 2025 pp. 3601-3601 10.1200/jco.2025.43.16_suppl.3601

3601 Background: Neoadjuvant immunotherapy provides considerable advantages for patients with dMMR/MSI-H rectal cancer. However, treatment strategies in r...

Dissecting two decades of thyroid carcinoma survival: Impact of gender, ethnicity, and income disparities.

Mishaal Munir, Asfand Yar Cheema, Shrishti Sinha et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18162

e18162 Background: Thyroid carcinoma is the most common endocrine malignancy, originating from follicular or parafollicular cells of the thyroid gland. It...

Molecular and clonal evolution of primary lesions vs brain metastasis of EGFR-mutated NSCLC: A retrospective cohort study.

Jairo Andrés Zuluaga Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20552

e20552 Background: Clonality is an intrinsic phenomenon of disease evolution, with specific clones conferring increased aggressiveness and apparent tropis...

Atezolizumab and stereotactic body radiation in metastatic, recurrent, or persistent cervical cancer: Results from a phase II multi-institutional study.

Kamran A. Ahmed, Allison Quick, Hye Sook Chon et al. Jun 01, 2025 pp. 5536-5536 10.1200/jco.2025.43.16_suppl.5536

5536 Background: Pembrolizumab is approved for PD-L1+ but not PD-L1 negative metastatic, recurrent, or persistent cervical cancer. Response rates to singl...

A phase II study of encorafenib and cetuximab (EC) beyond progression in combination with FOLFIRI in <i>BRAF</i> V600E-mutated metastatic colorectal cancer (mCRC).

Maria Alessandra Calegari, Lisa Salvatore, Michele Basso et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps3642

TPS3642 Background: BRAF V600E mutation occurs in approximately 10% of metastatic colorectal cancers (...

Rationale and study design of the KOV-HIPEC-02R (RECOVER): A randomized, multicenter, open-label phase III trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer.

Myong Cheol Lim, Ji Hyun Kim, Yun Hwan Kim et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps5628

TPS5628 Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) administered during interval cytoreductive surgery following neoadjuvant chemotherap...

DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM)—Final clinical results.

Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski et al. Jun 01, 2025 pp. 9506-9506 10.1200/jco.2025.43.16_suppl.9506

9506 Background: The DREAMseq trial compared efficacy and toxicity of the sequence of nivolumab/ipilimumab (N/I) followed by dabrafenib/trametinib (D/T) t...

Molecular and prognostic convergence of HR+/HER2– metastatic breast cancer (MBC) to a TNBC-like profile: Insights from circulating tumor DNA (ctDNA)-based genomic analysis across treatment lines.

Lorenzo Foffano, Carolina Reduzzi, Andrew A. Davis et al. Jun 01, 2025 pp. 1072-1072 10.1200/jco.2025.43.16_suppl.1072

1072 Background: While the transition to a triple negative (TNBC)-like profile represents a recognized mechanism of treatment resistance for hormone recep...

CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T-cell non-Hodgkin lymphoma: A first-in-human phase I clinical trial (NCT06420089).

Stefan K. Barta, Stephen J. Schuster, Jakub Svoboda et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps7087

TPS7087 Background: Autologous CART options for patients with relapsed or refractory (R/R) T-cell lymphomas (TCL) have faced challenges such as T-cell fra...

Phase 1a dose-escalation study of RS-0139: A novel tumor-targeted nanomedicine for advanced solid tumors.

Öztürk Ateş, Gulsah Nomak, Hakan Sedat Orer et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15006

e15006 Background: RS-0139 is a tumor-targeted prodrug designed to enhance the therapeutic index of docetaxel (DTX) by selectively delivering the active a...

Efficacy and safety of larotrectinib in patients with TRK fusion thyroid carcinoma: An updated analysis.

Marcia S. Brose, Maria E. Cabanillas, Jessica Jiyeong Lin et al. Jun 01, 2025 pp. 6094-6094 10.1200/jco.2025.43.16_suppl.6094

6094 Background: NTRK gene fusions are oncogenic drivers in various tumor types, including thyroid carcinoma (TC). Larotrectinib (laro) is the...

Implementation of a fellow-led tumor board to enhance learning and support in fellow continuity clinic.

Neha Hippalgaonkar, Ahmad M. Nassar, Karine Tawagi Jun 01, 2025 pp. 9000-9000 10.1200/jco.2025.43.16_suppl.9000

9000 Background: Hematology/oncology fellows in our program manage diverse and complex cases in continuity clinic (CC), including uncommon malignancies an...

The STAMPEDE2 trial: A site survey of current patterns of care, access to imaging, and treatment of metastatic prostrate cancer in Nigeria.

Nicholas David James, Omolara Aminat Fatiregun, Nwamaka Lasebikan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23059

e23059 Background: The STAMPEDE2 trial builds on the foundational STAMPEDE trial, which introduced innovative multi-arm treatment protocols for metastatic...

Concordance between a multidisciplinary tumor board and ChatGPT 4.0 in the management of genitourinary tumors: A real-world analysis.

Magda Arredondo, Omar A. Zayas, Christopher Cerda-Contreras et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23256

e23256 Background: Artificial intelligence (AI) is emerging as a valuable tool to support clinical decisions in oncology. Nevertheless, its practical impl...

Histologic comparison of the area of tumor bed after vacuum-assisted biopsy (VAB) or standard breast surgery in patients with early breast cancer after neoadjuvant systemic therapy (NST).

Nikolay Amirov, Petr Krivorotko, Asel Kudaybergenova et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12573

e12573 Background: The main goal of surgical intervention after achieving complete clinical response is to confirm it pathmorphologically. VAB of the tumo...

Comprehensive genomic profiling of Black and non-Hispanic White (NHW) men with prostate cancer (PCa).

Sharon H. Choi, Tolulope Tosin Adeyelu, Andrew Elliott et al. Jun 01, 2025 pp. 5022-5022 10.1200/jco.2025.43.16_suppl.5022

5022 Background: Racial disparities are evident in PCa, with Black men experiencing a higher incidence and worse survival compared to NHW patients (pts)....

A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor-naïve patients with metastatic uveal melanoma.

Joseph J Sacco, Justin C. Moser, Allison Betof Warner et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps9597

TPS9597 Background: Uveal melanoma (UM) is the most common primary intraocular malignancy, accounting for nearly 90% of ocular melanomas and up to 5% of m...

Demographic and regional trends and disparities in leukemia mortality in the United States (1999–2022): A comparative analysis of underlying and contributing cause models of death.

Arindam Bagga, Sahul Bharti, Tarun Parvataneni et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18517

e18517 Background: Leukemia, a hematological malignancy, ranks as the sixth leading cause of cancer-related deaths in males and seventh in females in the...

Practical geriatric assessment (PGA) implementation strategies and correlative evaluations (PACE-70): A hybrid implementation-effectiveness study in 3 community practices.

Gabriel Aleixo, Julianne Ani, William J. Ferrell et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps1661

TPS1661 Background: The use of a geriatric assessment to inform oncologic care for older persons with cancer is an evidence-based practice that improves p...

The prognostic and predictive value of the immunological gene signatures interferon gamma and TIDE for patients with liver metastases from uveal melanoma treated with isolated hepatic perfusion.

Måns Kadefors, Axel Nelson, Tobias Österlund et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21596

e21596 Background: Uveal melanoma (UM) is a rare cancer that often metastasizes to the liver. The SCANDIUM trial investigated the efficacy of isolated hep...

Clinicopathological features and prognostic implications of HER2-low in early-stage male breast cancer: A retrospective analysis.

Qiang Sa, Hangcheng Xu, Yan Wang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12518

e12518 Background: The clinicopathological and prognostic features of HER2-low female breast cancer (BC) have been widely studied. Current knowledge sugge...

Distribution of non-metastatic and metastatic disease in incidentally detected and screening-detected lung cancers.

Naseeruddin Naseem, Lisseth Beltran, Nevin Varghese et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20088

e20088 Background: Early detection of lung cancer is known to enhance outcomes by enabling treatment at earlier stages. This study explores whether the st...

Interim open-label phase 1 results of misetionamide (GP-2250): A small molecule antineoplastic targeting three major transcription factors.

Anup Kasi, Jose Luis Iglesias Jun 01, 2025 pp. 4177-4177 10.1200/jco.2025.43.16_suppl.4177

4177 Background: GP-2250 is a novel antineoplastic agent demonstrating effective activity on preclinical pancreatic cancer models alone or in combination...

Antibody drug conjugates treatment response score (ADC TRS) for sequencing trastuzuamb deruxtecan (T-DXd) and sacituzumab govitecan (SG) in advanced breast cancer (aBC).

Andi Cani, Scott A. Tomlins, Bryan Johnson et al. Jun 01, 2025 pp. 1053-1053 10.1200/jco.2025.43.16_suppl.1053

1053 Background: T-DXd, targeting HER2, is approved in hormone receptor positive or negative (HR+/-) HER2-low (1-2+ by immunohistochemistry [IHC]) and HR+...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page